Acomplia(
Generic Acomplia)
This medication
was invented by the french company Sanofi- Aventis to treat overweight
and obesity people. These amazing slimming pills are available in the
UK and other European countries, as the European Union has given its
approval in june 2006.
What
is Acomplia?
Acomplia
(rimonabant) is the first in a new class of therapeutic agents called
Cannabinoid-1 Receptor Blockers (CB1).
Acomplia
Ingredients:
Active
Ingredient: Rimonabant
Inactive Ingredients: Tablet core: maize starch, lactose monohydrate,
povidone K 30 (E1201), croscarmellose sodium (E468), sodium laurilsulfate
(E487), microcrystalline cellulose (E460), magnesium stearate
Tablet coating: lactose monohydrate, hypromellose 15 mPa.s (E464), titanium
dioxide (E171), macrogol 3000
Tablet polishing: carnauba wax (E903)
How does Acomplia work?
Acomplia
contains an ingredient, which is called rimonabant. Acomplia acts by
selectively blocking CB1 receptors found in the brain and in peripheral
organs important in glucose and lipid (or fat) metabolism, including
adipose tissue, the liver, gastrointestinal tract and muscle.
It works in the brain to produce feelings of fullness among users and
less food consumption is the result. . CB-1 receptors are located in
the Endo-cannabinoid system which regulates the food consumption in
the body. These receptors are overactive among the obese. Consumption
of Acomplia obstructs the CB-1 receptors in their regular functioning,
facilitating decreased appetite. A reduced appetite implicates that
you would eat in small portions, leading towards weight loss. Acomplia
acts by selectively blocking CB1 receptors found in the brain and in
peripheral organs important in glucose and lipid (or fat) metabolism,
including adipose tissue, the liver, gastrointestinal tract and muscle.
What
is Generic Acomplia used for?
These revolutionary
slimming pills are used to treat the obesity and help people to lose
weight. Patients with large waist circumference (defined as 102 cm/
40 inches in men and 88 cm/ 35 inches in women) will mostly benefit
from taking this revolutionary drug. Sanofi- Aventis, the frech company
who invented Acomplia argues that these amazing slimming pillscan also
prevent the risk of cardiovascular disease and also aid smokers quit
smoking.
Possible
side-effects of Acomplia?
Generic
Acomplia pills can show some minor side effects such as nausea, dizziness,
diarrhoea, vomiting, hot flushes, skin disorders and respiratory tract
infections. However, timely medical consultation can help treat these
side effects
Acomplia
Overdose
Experience
with Acomplia slimming pills overdosage is limited. In cases of overdose
the following symptoms were reported; headache, fatigue and insomnia,
euphoria. If an Acomplia overdose is suspected ensure that airways are
kept clear, monitor heart activity and contact a doctor immediately.
Generic
Acomplia should NOT be used in patients:
As a precautionary
measure; women with child bearing potential, expectant women, nursing
mothers, heart patients, and diabetics should not use Acomplia Sanofi
without consulting their health profesional. Also people who are allergic
to this medication or any of the inactive ingredients in Acomplia and
patients that have a galactose intolerance or glucose-galactose malabsorption.
Acomplia
Testing Still Going On
Acomplia is an appetite suppressant which works by acting on brain circuits
The drug
company Sanofi Aventis who make the weight loss medication Acomplia
say that they have not given up with the possibility of getting FDA
approval for the drug in the United States.
Last June
Sanofi Aventis suffered a big setback to the plans for Acomplia when
the Food & Drug Administration did not recommend that the obesity
drug should be approved citing concerns that some people got depressed
when using it. Sanofi Aventis however are pushing ahead with new clinical
trials and are showing how the medicine can be effective in treating
people who suffer from type 2 diabetes.
The company
Sanofi Aventis say that sometime in the year 2009 they will be resubmitting
new clinical test results to the Food & Drug Administration for
them to review and hopefully then they will approve the drug for sale
and marketing in America.
In the
meantime the drug company are upbeat about the sales of this weight
loss medication in Europe where it has been fully approved for over
a year now. In Europe since the EMEA gave approval for the medication
it has been sold in most European countries being especially popular
in Germany where it is estimated that as many as 50,000 people are using
it at present.
Acomplia
is an appetite suppressant which works by acting on some brain circuits
that send signals telling people that they are hungry. Interestingly
these brain circuits are identical to the ones that give people the
munchies when they smoke cannabis. Acomplia however has the opposite
effect on these brain circuits to the cannabis and stops people from
thinking about food and feeling hungry.
If the
Food & Drug Administration gives the Acomplia weight loss drug full
approval it will be sold in America under a different name, Zimulti.
The American market for weight loss drugs is by far the largest market
in the world and the french company are therefore very keen to get approval
for Acomplia over there.
Acomplia
May Lower Cholesterol Too
Their cholesterol levels greatly improved...
The Acomplia
weight loss drug has been the subject of new clinical testing done
by its manufacturer Sanofi Aventis in France. The research that used
lab rats saw that when the rodents were given tiny doses of the Acomplia
obesity drug their cholesterol levels greatly improved and it was
also noted that the drug could lessen liver damage.
The rats
in the study were given Acomplia every day over an 8 week period and
at the end of this the researchers said that the rats livers had not
enlarged as much as other rats that were not given the medicine. They
also noted that the level of fat in the livers of the rats was lower
too. They also examined the blood of the rats to assess liver damage
and noted a positive result also. The researchers also said that there
was less of a particular inflammation protein that is known to create
insulin resistance and cirrhosis in the liver. The research appeared
in the clinical journal called Hepatology.
The Acomplia
pills are approved for sale in Europe by the EMEA, but recently was
denied approval in America by the Food & Drug Administration.
In America there were concerns that depressed people who took the
Acomplia weight loss drug could suffer from further depression and
people who have a history of depression should not use this obesity
medication.
Acomplia
is an appetite suppressant that works differently to most other appetite
suppressants by acting on receptors in the brain that cause you to
feel hungry. Basically the drug tricks you into thinking that you
are not hungry and so as a result you eat less. The United Kingdom
was the first nation in Europe to start selling the Acomplia weight
loss medication and the french company Sanofi Aventis say they are
very pleased with the take up in the UK.
